Supernus Acquires Sage Therapeutics in Up to $795M Deal to Expand Neuropsychiatry Portfolio
Supernus Pharmaceuticals is acquiring Sage Therapeutics in a $561 million deal, boosting Sage's stock significantly amid recent setbacks and pipeline challenges, with the deal offering a premium over previous bids and potentially valuing Sage at up to $795 million if milestones are met.